Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the third part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, notes that in a crowded weight management landscape, marketers play a critical role in combating misinformation by ensuring healthcare providers and patients have clear, accurate information on the safety, efficacy, and access pathways of FDA-approved treatments.

Communicating the Value of Approved Therapies

Articles

A new JAMA Network Open study highlights how over-the-counter oral contraceptives can reduce barriers to care, especially for uninsured, rural, and adolescent populations, amid shifting federal policies on reproductive health.

A Deep Dive Into FDA’s Approval of First OTC Birth Control Pill 

Podcasts

This episode of Pharma Pulse covers healthcare advocates’ push for a $50 billion Rural Health Transformation Program, new research showing pneumococcal vaccination gaps among adults with celiac disease, and Novartis’ $5.7 billion licensing agreement with Monte Rosa Therapeutics for protein degrader therapies.

Pharma Pulse: Rural Hospitals Seek $50B Lifeline, Vaccination Gaps Found in Celiac Patients, and Novartis Signs $5.7B Licensing Deal

In the second part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, points out that as patient fatigue grows with injectable therapies, oral alternatives are emerging as vital tools for clinicians and patients alike, expanding choice, improving access, and supporting more personalized obesity treatment strategies.

Oral Weight Loss Treatments Offer Patients and Clinicians New Options in Obesity Care

The collaboration seeks to reduce drug waste, prevent errors, and support more reliable delivery of life-saving therapies to patients worldwide.

New Phononic–Peltier Partnership Targets Safer, Smarter Cold Chain for Medicines

This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.

Pharma Pulse: FDA Accelerates Non-Opioid Pain Drug Development, FTC Targets Non-Competes in Healthcare, and DHL Expands Last-Mile Logistics

In the first part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, explains how predictable, affordable pricing models for FDA-approved oral weight loss drugs can reduce barriers to care, improve long-term adherence, and support better outcomes for patients managing chronic obesity.

Consistent Cash-Pay Options Could Transform Access to Obesity Medications

The deal will integrate SDS Rx’s specialized delivery network of US locations into DHL’s Life Sciences & Healthcare division, strengthening same-day and final-mile services as demand for specialty pharma and patient-centered logistics continues to rise.

DHL Supply Chain Acquires SDS Rx, Expanding Last-Mile Healthcare Logistics

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

In the final part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, details how in a post-COVID landscape, technologies that track and regionalize hospital inventory could become critical tools for state and local health departments, ensuring visibility, preparedness, and smarter resource allocation during future disruptions.

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs